Testing effectiveness (Phase 2)Study completedNCT02156804
What this trial is testing
A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172)
Who this might be right for
Melanoma
Bristol-Myers Squibb 1,009